# RNN 1st Gen Model Mylan Inc. Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
May 3, 2018
Deal entry on
May 3, 2018
0.45%Expected margin
70.79% successful of 89 deals
$ 14.82 Last close price
at 22-sep-2020

MYL

Model's trade recommendations 0.69% Return for period

3.56% Annual return

$18.93B Market Cap

β 1.35  

MYL

Model (following trade recommendations)

MYL

Underlying stock

S&P 500

Index
Return for period 0.69%
-7.55%
1.78%
52wk return 1.84%
-25.64%
16.82%
52wk Range
13.26—22.85
2000.54—2399.63
Sortino ratio 0.32
Sharpe ratio 0.28
Norm. RMSE 0.96%
Downside risk 14.30%
Volatility 0.00%
  • STRONG BUY Analysts consensus recommendation

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Mylan Inc. (MYL) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for MYL model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for MYL.

Model is being retrained on a daily basis.

Float 511M
P/E 8.06
Shares Outstanding 515M
% Held by Insiders 0.69%
% Held by Institutions 84.16%
EPS (last reported FY) $4.56
EPS (last reported Q) $1.43
EPS, estimated (last reported Q) $1.41
Total revenues $12 B
Net income $1 B